ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Association of current Statin use with incident age-related macular degeneration: using time-varying propensity scores.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeStatins exhibit pleiotropic properties that may influence age-related macular degeneration (AMD) progression. However, since their prescription is predominant in older populations at high cardiovascular risk, a lack of robust approach to control for confounding by indication could partly explain controversial results in previous studies. We therefore analyzed the association of current statin use with incident AMD using time-varying propensity score-based inverse probability of treatment weighting (IPTW).
methodsAnalysis of data from the ALIENOR study, a 14-year French prospective population-based cohort of 963 adults aged 73 years and older in Bordeaux, followed every 2-3 years (2006-2020), with repeated assessments of statin use through a face-to-face questionnaire. AMD status was assessed using retinal multimodal imaging every 2-3 years (2006-2020). Incident intermediate and advanced AMD were analyzed separately. Combining time-varying IPTW balancing and covariates adjustment, we fitted time-dependent Cox proportional hazards models to estimate adjusted hazard ratios (aHRs [95% confidence intervals]) for incident AMD associated with current statin use (defined as using statin within the last three years prior to the current visit).
resultsOver a median follow-up of 7 years, cumulative incidence was 36% and 10% among the participants analyzed for intermediate (n = 475) and advanced (n = 692) AMD, respectively. After accounting for confounding by indication, current statin use was not associated with increased hazards of intermediate (aHR: 1.02 [0.72-1.45]) and advanced (aHR: 1.08 [0.61-1.91]) AMD. Analyses of statin subtypes (lipophilic and hydrophilic) and all lipid-lowering agents consistently yielded non-significant association with the hazards of AMD. Findings were consistent across sensitivity analyses.
conclusionThese findings suggest that, after controlling for confounding by indication, statins may not substantially influence the risk of developing intermediate or advanced AMD in older adults, despite the biological plausibility.
Indexed as
Identifiers
41408005What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.